hares of Kamada’s common stock are scheduled to begin trading on the NASDAQ Global Select Market under the symbol KMDA on May 31, 2013. All of the shares of common stock are being offered by Kamada.

In addition, Kamada has granted the underwriters a 30-day option to purchase up to an additional 837,395 shares of common stock to cover over-allotments, if any.

The company said that its ordinary shares are listed on the Tel Aviv Stock Exchange under the symbol “KMDA.”

Previously, the company said that On May 12, 2013, the last reported sale price of its ordinary shares on the TASE was NIS 38.24, or $10.75, per share.

Kamada is an orphan drug focused, plasma-derived protein therapeutics company with an existing marketed product portfolio and a robust late-stage product pipeline. It develops and produces specialty plasma-derived protein therapeutics and currently market these products through strategic partners in the United States and directly, through local distributors, in several emerging markets. It said it use its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin in a high purity, liquid form, as well as other plasma-derived protein.

The company said it incurred an operating loss of $1.3 million for the three months ended March 31, 2013 and generated an operating profit of $4.2 million for the year ended December 31, 2012. The company said its total revenues have grown from approximately $14.4 million in the year ended December 31, 2009 to $72.7 million in the year ended December 31, 2012, representing a 71% compound annual growth rate.